Welcome to our dedicated page for Addex Therapeutics SEC filings (Ticker: ADXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company focused on small-molecule allosteric modulators. As a foreign issuer listed on the NASDAQ Capital Market, Addex Therapeutics reports to the SEC using forms such as Form 20-F for annual reports and Form 6-K for current information.
Recent Form 6-K filings for Addex Therapeutics include press releases, unaudited interim condensed consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations. These documents are often incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, as disclosed in the filings. The company’s reports also emphasize that its business faces significant risks and refer readers to risk factors discussed in its Form 20-F.
On Stock Titan, Addex Therapeutics filings are updated from the SEC’s EDGAR system, and AI-generated summaries can help explain the structure and key points of lengthy documents. Users can review annual disclosures on Form 20-F, interim information and press releases furnished on Form 6-K, and other registered offerings referenced in the company’s F-3 and S-8 statements.
For those analyzing ADXN, this filings page offers a structured view of Addex Therapeutics’ regulatory history, including financial statement presentations, discussions of results of operations, and risk disclosures that the company highlights as important to understanding its business and prospects.
Addex Therapeutics Ltd. director and chief medical officer Roger Mills reported his initial holdings. He directly owns 785,976 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options over 50,000 shares, exercisable at $0.0640 per share.
The options began vesting in equal monthly installments over four years from the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. director Vincent Michael Lawton has filed a Form 3 reporting his initial beneficial ownership in the company. He holds 2,507,987 shares of Common Stock listed on the SIX Swiss Exchange and a stock option award over 501,598 shares of Common Stock.
The stock options carry an exercise price of $0.064 per share, based on a CHF-to-USD exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026. These options began vesting in equal monthly installments over a four-year period starting January 8, 2024 and expire on January 7, 2034.
Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares. These options are rights to buy shares at fixed prices and represent existing compensation grants, not new share purchases or sales.
The filing lists several option grants with exercise prices of $0.1660, $0.0550, and $0.0640 per share, expiring between 2027 and 2034. According to the footnotes, each option gives the right to buy one ADXN share, vesting in equal monthly installments over four years, and the exercise prices are reported in U.S. dollars using a $1.2769 per CHF $1.00 exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. executive Mikhail Kalinichev filed an initial ownership report showing his equity stake in the company. He directly holds 306,765 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 200,000 shares at an exercise price of $0.0640 per share. The option is exercisable from August 1, 2024, vests in equal monthly installments over four years, and expires on January 7, 2034. Each option entitles him to purchase one ADXN share on SIX Swiss Exchange.
Addex Therapeutics Ltd. director Raymond George Hill filed an initial ownership report showing his equity position in the company. He holds 1,365,532 shares of Common Stock listed on the SIX Swiss Exchange and a stock option over 273,107 shares of Common Stock.
The stock option has an exercise price of $0.0640 per share, becomes exercisable in equal monthly installments over a four-year period beginning on the exercisable date, and expires on January 7, 2034. The exercise price reflects conversion from Swiss francs at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. Chief Executive Officer Timothy Mark Dyer filed an initial insider ownership report. He reports direct ownership of 16,848,979 shares of common stock listed on SIX Swiss Exchange. This filing does not show new purchases or sales; it establishes his existing position.
Dyer also holds stock options giving the right to buy 3,369,796 shares of common stock at an exercise price of $0.064 per share. These options vest in equal monthly installments over four years starting on the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars based on a stated CHF-to-USD exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. director Jason Raleigh Nunn filed an initial ownership report showing his existing stake in the company. He directly holds 219,561 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 50,000 shares of Common Stock.
The stock options have an exercise price of $0.0640 per share, become exercisable in equal monthly installments over a four-year period beginning on the exercise start date of January 8, 2024, and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a stated CHF-to-USD exchange rate.
Addex Therapeutics director Isaac Manke reported his initial holdings. He directly owns 219,561 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options on 50,000 shares of Common Stock with a $0.064 exercise price.
The stock options began vesting in equal monthly installments over a four-year period starting on January 8, 2024 and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a CHF-to-USD exchange rate as of March 12, 2026.
Addex Therapeutics furnished a report detailing new preclinical data supporting its mGlu7 negative allosteric modulators as a potential treatment for anxiety and fear-related disorders. The data, published in Molecular Psychiatry, focus on ADX71743, a highly selective mGlu7 modulator.
In rat models of fear learning and memory, ADX71743 disrupted fear memory reconsolidation after recall, reducing reinstatement of fear and acting within a defined time window. Electrophysiology showed modulation of glutamatergic transmission at thalamus-to-amygdala synapses, with similar synaptic effects observed in human brain tissue, providing early translational support.
The company emphasizes mGlu7 as a promising target for conditions such as PTSD, OCD, anxiety, depression, drug abuse and schizophrenia, and notes its broader allosteric modulator portfolio, including dipraglurant for brain injury recovery and partnered and spin-out programs in GABAB, M4 and mGlu7.
Addex Therapeutics furnished a report highlighting progress at its spin-out company Neurosterix, which has started a Phase 1 clinical study of NTX-253, an oral positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia. The first-in-human trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Neurosterix was spun out of Addex in April 2024 and raised $65 million in a Series A financing led by funds affiliated with Perceptive Advisors; Addex retains a 20% equity interest in the company. The filing also reiterates Addex’s broader neurology-focused pipeline, including lead candidate dipraglurant for brain injury recovery, partnered and independent GABAB PAM programs for substance use disorders and chronic cough, and its investments in Neurosterix and Stalicla.